Abstract
The brain is an organ which is at once enriched in transition metals and highly susceptible to oxidative stress. By virtue of its high affinity for copper the Alzheimers amyloid protein (Aβ) is capable of catalytic generation of neurotoxic H2O2 while its aggregation and deposition are zinc-dependent. These properties are exaggerated by conditions present in the aging brain. Amyloid from human brain specimens can be solubilized by the application of selected Cu / Zn chelators thus demonstrating the role of metals in amyloid architecture. Similarly, the toxicity of the metal / Aβ complex is ameliorated by metal complexing agents. Clioquinol, a bioavailable Cu / Zn chelator has been successfully used to inhibit amyloid deposition in a transgenic animal model for Alzheimers disease and is presently undergoing human efficacy trials. Keywords: metallochemistry, alzheimer disease, clioquinol
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Current Medicinal Chemistry-Immunology, Endocrine & Metabolic Agents
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.